CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	3.41M 2.98M 2.75M 2.54M 4.78M 329M 4.89M 32.89M 12.94M 161M 12.81M 12.53M 554M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	25.27M 22.08M 20.37M 18.78M 35.4M 2.43B 36.18M 244M 95.79M 1.19B 94.89M 92.81M 4.1B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	2025-07-20
Kun Qian DFI	Director of Finance/CFO	44	2025-05-15
Chun Hua Wang COO	Chief Operating Officer	54	2016-12-31

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	2013-03-31
Zhen Bo Su BRD	Director/Board Member	50	2023-03-20
Thomas Folinsbee BRD	Director/Board Member	59	2023-03-20

EntreMed Inc Stock Nasdaq

Stocks

US29382F2020

Pharmaceuticals

Valuation: EntreMed Inc

Latest news : EntreMed Inc

Press Releases: EntreMed Inc

Managers and Directors: EntreMed Inc

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.03%	-0.13%	+54.87%	+154.49%	1,051B
JOHNSON & JOHNSON	-0.63%	-2.61%	+52.73%	+49.09%	609B
ABBVIE INC.	+0.10%	+2.55%	+37.59%	+78.87%	450B
ROCHE HOLDING AG	-0.64%	+0.51%	+30.05%	+21.40%	330B
NOVARTIS AG	-1.24%	-0.98%	+34.75%	+35.63%	284B
ASTRAZENECA PLC	-1.26%	-1.17%	+21.79%	+16.51%	263B
NOVO NORDISK A/S	-0.40%	+1.20%	-20.10%	-40.54%	223B
AMGEN INC.	+0.08%	+1.53%	+23.69%	+56.91%	198B
GILEAD SCIENCES, INC.	-0.61%	+1.48%	+23.14%	+66.80%	167B
Average	-0.52%	+0.41%	+28.72%	+48.80%	397.23B
Weighted average by Cap.	-0.41%	-0.05%	+38.12%	+73.47%

	2024	2025
Net sales	28.54M 24.94M 23.01M 21.21M 39.98M 2.75B 40.87M 275M 108M 1.35B 107M 105M 4.63B	20.71M 18.1M 16.7M 15.4M 29.02M 1.99B 29.66M 200M 78.52M 977M 77.78M 76.08M 3.36B
Net income	-39.26M -34.31M -31.66M -29.18M -55M -3.78B -56.22M -378M -149M -1.85B -147M -144M -6.37B	-48.06M -42M -38.75M -35.72M -67.33M -4.63B -68.82M -463M -182M -2.27B -180M -177M -7.8B
Net Debt	6.05M 5.29M 4.88M 4.5M 8.48M 583M 8.66M 58.31M 22.94M 285M 22.72M 22.22M 982M	21.85M 19.1M 17.62M 16.24M 30.62M 2.1B 31.3M 211M 82.85M 1.03B 82.07M 80.27M 3.55B

End-of-day quote Nasdaq Other stock markets
- ^USD	-